Gastric Cancer
D9803C00001: A Phase III, Multicentre, Randomised Controlled Study of Sonesitatug vedotin in Combination with Capecitabine with or without Rilvegostomig in First-line Claudin18.2-positive, HER2‑negative, Advanced/Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (CLARITY‑Gastric 02)
- Details
ClinicalTrials.gov ID:
NCT07431281
Diagnosis Type:
NA
USOR Number:
- Address
,
P: